Latest News

Home breadcrumb arrow Latest News

Dr. Michael Kitt was appointed CEO of Axalbion

February 6, 2020

Dr. Kitt joined Axalbion as Chief Executive Officer in November 2019, bringing more than 30 years of clinical development experience and industry expertise.

Read more

Results of an exploratory study in refractory chronic cough patients suggest that AX-8 reduces awake cough frequency

June 27, 2019

Results of the AX8-001 study (EudraCT no. 2017-003108-27) titled "A PILOT STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF AX-8 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH" are available on EU Clinical Trials Register:

Read more

Welcome to Axalbion’s new website

June 20, 2019

If you need further information please feel free to contact us.

Read more